Organization

OREBRO LANS LANDSTING

Swedish regional healthcare authority contributing clinical data, patient populations, and health system expertise to European health and AI research.

Public authorityhealthSEThin data (2/5)

H2020 projects

As coordinator

Total EC funding

€879K

Unique partners

142

What they do

Their core work

Region Örebro County is a Swedish regional public authority responsible for healthcare delivery and regional development in the Örebro area. In H2020, they contribute clinical expertise and real-world patient data to European health research, particularly in surgical outcomes, autoimmune disease, and cancer care. They bring the perspective of a healthcare provider dealing with actual patient populations, making them valuable for projects that need clinical validation sites and health economic data. Their involvement spans from specialized surgical trials to AI-driven cancer care prediction.

Core expertise

What they specialise in

Clinical trials in vascular surgerysecondary

1 project

PAPA-ARTIS is a randomized controlled trial focused on paraplegia prevention during aortic aneurysm repair, indicating direct surgical and clinical trial capability.

AI and big data in cancer caresecondary

1 project

ASCAPE applies artificial intelligence and machine learning to predict cancer patient quality of life and health outcomes using real health economic data.

Autoimmune disease researchsecondary

1 project

3TR investigates molecular mechanisms of treatment non-response in autoimmune and inflammatory diseases using single-cell data and integrative genomics.

Responsible healthcare innovation and governanceemerging

1 project

CHERRIES focuses on responsible research and innovation in healthcare, including co-creation and regional governance of health services.

Health data and predictive modelingemerging

2 projects

Both ASCAPE and 3TR involve predictive modeling, disease trajectory analysis, and data-driven analytics applied to patient populations.

Evolution & trajectory

How they've shifted over time

Early focus

Surgical trials and autoimmune research

Recent focus

AI-driven healthcare and governance

Their early H2020 involvement (2017-2019) centered on traditional clinical research — a surgical randomized controlled trial for aortic aneurysm repair and molecular-level autoimmune disease research. By 2020, the focus shifted decisively toward digital health: AI-driven cancer care prediction, big data analytics, and responsible innovation governance. This mirrors a broader transition from being a clinical data contributor to an active participant in data-driven and AI-powered healthcare transformation.

Moving from traditional clinical participation toward AI, big data analytics, and responsible governance of digital health — expect future involvement in precision medicine and health data infrastructure projects.

Collaboration profile

How they like to work

Role: specialist_contributorReach: European22 countries collaborated

Region Örebro County exclusively joins projects as a participant or third party — they have never coordinated an H2020 project. They operate within large consortia (142 unique partners across 4 projects), suggesting they serve as a clinical site or regional healthcare contributor rather than a research driver. This makes them a reliable, low-friction partner for consortia that need a real healthcare system to validate solutions against.

Despite only 4 projects, they have built connections with 142 unique partners across 22 countries, reflecting participation in large-scale European health consortia. Their network is broad and pan-European rather than concentrated in any single region.

Why partner with them

What sets them apart

As a regional healthcare authority (not a university or research institute), Region Örebro County offers something most academic partners cannot: direct access to a functioning public healthcare system with real patient populations, clinical workflows, and health economic data. This makes them particularly valuable for projects that need to validate digital health tools, test clinical interventions, or analyze healthcare demand in a real-world setting. Their combination of surgical, oncological, and autoimmune clinical expertise is unusually broad for a single regional authority.

Notable projects

Highlights from their portfolio

ASCAPE
Their largest funded project (EUR 405,000), applying AI and machine learning to cancer patient outcomes — represents their clearest move into digital health.
PAPA-ARTIS
A long-running randomized controlled trial (2017-2024) on paraplegia prevention in aortic surgery, demonstrating capacity for rigorous clinical research.
3TR
Running until 2026, this large-scale project on treatment non-response in autoimmune diseases involves advanced genomics and stratification — their longest-term commitment.

Cross-sector capabilities

Digital health and AI applicationsHealth data infrastructure and analyticsRegional governance and responsible innovationPublic health policy and co-creation

Analysis note: With only 4 projects (none as coordinator) and limited funding, this profile is based on a small evidence base. The organization's true capabilities likely extend well beyond what H2020 participation alone reveals. One project (3TR) lists them as third party with no direct EC funding, further limiting insight into their active research capacity.